Analysts See $-0.14 EPS for Evoke Pharma, Inc. (EVOK)

July 14, 2018 - By Pearl Odom

Evoke Pharma, Inc. (NASDAQ:EVOK) LogoInvestors sentiment decreased to 0.33 in Q1 2018. Its down 1.30, from 1.63 in 2017Q4. It turned negative, as 5 investors sold Evoke Pharma, Inc. shares while 4 reduced holdings. 0 funds opened positions while 3 raised stakes. 2.25 million shares or 16.84% less from 2.71 million shares in 2017Q4 were reported.
5,100 are owned by Wells Fargo & Company Mn. Pnc Gru has invested 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK). Deutsche National Bank Ag holds 0% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK) for 200,000 shares. 683 Cap Mgmt Limited Liability Company holds 0.02% of its portfolio in Evoke Pharma, Inc. (NASDAQ:EVOK) for 114,300 shares. 66,078 were accumulated by Blackrock Incorporated. Comml Bank Of New York Mellon reported 24,908 shares or 0% of all its holdings. Geode Llc reported 23,048 shares. Creative Planning reported 100,000 shares. Sphera Funds Management has invested 0.12% in Evoke Pharma, Inc. (NASDAQ:EVOK). Morgan Stanley holds 4,450 shares. Advisers Ltd holds 0% or 15,566 shares in its portfolio. 25,000 were reported by J Goldman L P. Knoll Cap L P invested in 0.59% or 275,000 shares. State Treasurer State Of Michigan reported 0.01% in Evoke Pharma, Inc. (NASDAQ:EVOK). Citigroup owns 0% invested in Evoke Pharma, Inc. (NASDAQ:EVOK) for 500 shares.

Analysts expect Evoke Pharma, Inc. (NASDAQ:EVOK) to report $-0.14 EPS on August, 13.They anticipate $0.13 EPS change or 48.15 % from last quarter’s $-0.27 EPS. After having $-0.16 EPS previously, Evoke Pharma, Inc.’s analysts see -12.50 % EPS growth. The stock increased 2.27% or $0.06 during the last trading session, reaching $2.7. About 23,135 shares traded. Evoke Pharma, Inc. (NASDAQ:EVOK) has risen 16.02% since July 14, 2017 and is uptrending. It has outperformed by 3.45% the S&P500.

Evoke Pharma, Inc. (NASDAQ:EVOK) Ratings Coverage

Among 2 analysts covering Evoke Pharma (NASDAQ:EVOK), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Evoke Pharma had 6 analyst reports since March 6, 2018 according to SRatingsIntel. The company was maintained on Thursday, March 8 by FBR Capital. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 6. The firm earned “Buy” rating on Monday, April 2 by H.C. Wainwright. The stock of Evoke Pharma, Inc. (NASDAQ:EVOK) earned “Buy” rating by H.C. Wainwright on Tuesday, June 5. FBR Capital maintained Evoke Pharma, Inc. (NASDAQ:EVOK) on Tuesday, June 5 with “Buy” rating. H.C. Wainwright maintained Evoke Pharma, Inc. (NASDAQ:EVOK) rating on Thursday, May 3. H.C. Wainwright has “Buy” rating and $900 target.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $45.29 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

Evoke Pharma, Inc. (NASDAQ:EVOK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.